PCNA and breast carcinoma: The co-treatment of butyrate with these death receptors upregulated proliferating cell nuclear antigen (PCNA) and levels of P21waf1, indicating their beneficial interactions to potentiate apoptotic cell death as observed in the co-treatments, which could have a number of clinical implications in managing breast cancer [28].